SEARCH:   Advanced

Blood, 15 March 2006, Vol. 107, No. 6, pp. 2578-2584. Prepublished online as a Blood First Edition Paper on November 17, 2005; DOI 10.1182/blood-2005-06-2462. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-06-2462v1 107/6/2578    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schönland, S. O. Articles by Gahrton, G. Search for Related Content PubMed PubMed Citation Articles by Schönland, S. O. Articles by Gahrton, G. Related Collections Immunobiology Neoplasia Transplantation Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation Stefan O. Schönland, Henk Lokhorst, Agnes Buzyn, Veronique Leblond, Ute Hegenbart, Giuseppe Bandini, Andrew Campbell, Enric Carreras, Augustin Ferrant, Leanthe Grommisch, Peter Jacobs, Nicolaus Kröger, Giorgio La Nasa, Nigel Russell, Pierre Zachee, Hartmut Goldschmidt, Simona Iacobelli, Dietger Niederwieser, Gösta Gahrton, for the Chronic Leukemia Working Party (CLWP), Myeloma Subcommittee of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) From the University of Heidelberg, Germany; University Medical Centre Utrecht, Utrecht, Netherlands; Hopital Necker, Paris, France; Pitie Salpetriere, Paris, France; Institute of Hematology, Bologna University, Bologna, Italy; Oxford Radcliffe Hospital, Oxford, United Kingdom; Institute of Hematology Barcelona, Barcelona, Spain; Cliniques Universitaires St Luc, Brussels, Belgium; University of Leipzig, Leipzig, Germany; Department of Haematology and BMT Unit, Cape Town, South Africa; University Hospital Eppendorf, BMT Centre, Hamburg, Germany; Centro Trapianti di Midollo Osseo, Cagliari, Italy; Nottingham City Hospital, Nottingham, United Kingdom; AZ Stuivenberg, Antwerpen, Belgium; Dept of Medical Statistics, European Research Support Office, Leiden, Netherlands; and Karolinska University Hospital, Huddinge, Stockholm, Sweden. Using the European Group for Blood and Marrow Transplantation (EBMT) registry, we retrospectively studied 19 patients with AL (amyloid light-chain) amyloidosis who underwent allogeneic (allo; n = 15) or syngeneic (syn; n = 4) hematopoietic stem cell transplantation (SCT) between 1991 and 2003. For allo-SCT, full-intensity conditioning was used in 7 patients and reduced-intensity conditioning (RIC) in 8 patients. Engraftment was durable in 12 of those 15 patients. The median follow-up time is 19 months. Kaplan-Meier probabilities of overall and progression-free survival were 60% and 53% at 1 year, respectively. Overall, 40% of patients died of transplant-related mortality (TRM). Best hematologic response after SCT was complete remission (CR) and partial remission (PR) in 8 and 2 patients, respectively, leading to an organ response in 8 of these patients. Seven of the 10 patients in remission are long-term survivors. In 5 of 7 evaluable patients in CR, chronic graft-versus-host disease (GvHD) was observed, indicating the contribution of immune effects to disease control. The main clinical problem was cardiac failure in patients with poor performance status due to amyloidosis or in combination with severe infections. These data suggest that allo-SCT might be a promising and potentially curative treatment modality for selected patients with AL amyloidosis. (Blood. 2005;107:2578-2584) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Allo attack on amyloidosis Morie A. Gertz Blood 2006 107: 2213-2214. [Full Text] [PDF] This article has been cited by other articles: F.-U. Sack, A. Kristen, H. Goldschmidt, P. A. Schnabel, T. Dengler, A. Koch, and M. Karck Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 257 - 262. [Abstract] [Full Text] [PDF] V. Sanchorawala Light-Chain (AL) Amyloidosis: Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1331 - 1341. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020